Palivizumab and RSV prevention
Open Access
- 1 July 2000
- journal article
- letter
- Published by BMJ in Archives of Disease in Childhood
- Vol. 83 (1) , 87a-87
- https://doi.org/10.1136/adc.83.1.87a
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- RSV preventionArchives of Disease in Childhood, 2000
- Rehospitalization for Respiratory Syncytial Virus Among Premature InfantsPublished by American Academy of Pediatrics (AAP) ,1999
- Respiratory syncytial virus infectionThe Lancet, 1999
- Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIVPediatrics, 1998
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPediatrics, 1998
- Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants With Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin ProphylaxisPediatrics, 1997
- Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young ChildrenNew England Journal of Medicine, 1993
- Cost Effectiveness of Beractant in the Prevention of Respiratory Distress SyndromePharmacoEconomics, 1993